BACKGROUND/AIMS: The determination of neuron-specific enolase (NSE) is relatively frequently requested in the differential diagnosis of small-cell lung carcinoma and non-small-cell lung carcinoma. The individual results of different immunoassays are often not comparable, which has been confirmed by long-term external quality assessments. In this study, we assessed the possible sources of these differences. METHODS: More than 3,000 NSE analyses were performed using seven different immunoassays: DELFIA (PerkinElmer), Elecsys 2010 or Modular Analytics E 170 (Roche), Kryptor (B.R.A.H.M.S.), the enzyme-linked immunosorbent assay DRG and three assays based on immunoradiometric assays (DiaSorin, Immunotech and Schering-CIS). The following parameters were evaluated: precision profile of the individual methods, linearity on dilution and modified recovery, comparability and discrimination of immunoassays, sensitivity, and specificity. RESULTS: There were differences in the correlation of values of certain low-concentration specimens. Some assays correlate well while others do not (up to fivefold difference), especially in the case of controls prepared synthetically. Therefore, the current non-standardized preparation of controls is questionable in our opinion. In the cutoff range, the difference in the results of native samples did not exceed its double value. The variation in values >100 microg/l obtained with different assays is <40%. CONCLUSION: Our results confirmed expected matrix interferences especially in the range of normal and cutoff NSE concentrations. Another source of discrepancies can be attributed to different antibody affinity to alphagamma- and gammagamma-enolase isoenzymes. Finally, improper settings of cutoff values also contribute to the different discrimination of the methods.
- MeSH
- adenokarcinom krev enzymologie MeSH
- biotest * MeSH
- ELISA MeSH
- fosfopyruváthydratasa krev MeSH
- lidé MeSH
- malobuněčný karcinom krev enzymologie MeSH
- nádorové biomarkery metabolismus MeSH
- nádory plic krev enzymologie MeSH
- nemalobuněčný karcinom plic krev enzymologie MeSH
- senzitivita a specificita MeSH
- spinocelulární karcinom krev enzymologie MeSH
- studie případů a kontrol MeSH
- velkobuněčný karcinom krev enzymologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Research Support, N.I.H., Extramural MeSH
- srovnávací studie MeSH
- Názvy látek
- fosfopyruváthydratasa MeSH
- nádorové biomarkery MeSH
Serum concentrations of tissue polypeptide antigen (TPA) were examined by an immunoradiometric technique in 114 patients with bronchogenic carcinoma and in 55 patients with noncancerous lung diseases. The sensitivity of TPA examination in bronchogenic carcinoma was 67.5% and was increased in advanced stages of the disease. No statistically significant differences were observed between histologic types of bronchogenic carcinoma. In nonmalignant lung diseases, elevated levels of TPA were observed in 21.8% of patients. TPA is of little value in the diagnosis of bronchogenic carcinoma; however, it may be useful as an auxiliary criterion for staging.
- MeSH
- adenokarcinom krev patologie MeSH
- bronchogenní karcinom krev patologie MeSH
- dospělí MeSH
- imunoradiometrická analýza metody MeSH
- karcinom krev patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- malobuněčný karcinom krev patologie MeSH
- nádorové biomarkery krev MeSH
- nádory plic krev patologie MeSH
- peptidy krev MeSH
- plicní nemoci krev MeSH
- referenční hodnoty MeSH
- senioři MeSH
- spinocelulární karcinom krev patologie MeSH
- staging nádorů MeSH
- tkáňový polypeptidový antigen MeSH
- velkobuněčný karcinom krev patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- nádorové biomarkery MeSH
- peptidy MeSH
- tkáňový polypeptidový antigen MeSH
